NEW YORK (GenomeWeb News) – Life Technologies this week named Alan Sachs as head of global research and development and Ronnie Andrews as president of medical sciences.
Sachs was previously the vice president of exploratory and translational sciences for Merck Research Laboratories, where he spent 10 years in various leadership roles, Life Tech said. Prior to that Sachs served an associate professor of biochemistry and molecular biology at the University of California, Berkeley, and as a Whitehead fellow at the Whitehead Institute for Biomedical Research.
Andrews joins Life Tech from GE Molecular Diagnostics, where he served as a segment leader following GE's 2010 acquisition of Clarient, where Andrews was CEO. Andrews has also held executive positions with Abbott Diagnostics, Roche Diagnostics, and Immucor.
As president of medical sciences at Life Tech, Andrews will help expand Life's presence in the diagnostics and personalized medicine space through strategies including short- and long-term partnerships, the company said.
Marc LePage has been named president and CEO of Genome Quebec. LePage previously was involved in the founding of Genome Canada, he was a special advisor on climate change and energy for the Embassy of Canada in the US, and he was a Consul General at the Canadian Consulate in San Francisco.
Prometheus Laboratories has appointed Anthony Yost to be senior VP and chief commercial officer. Yost formerly was CCO at EKR Therapetuics, GM for the Western US operating unit of Novartis Pharmaceuticals, president of Innovex, the commercial solutions division of Quintiles International, and he held other executive and management posts at other large and small life sciences companies.
Becton Dickinson's shareholders this week reelected its board of directors to serve until the company's 2013 meeting or until their respective successors are elected. The directors include Claire Fraser-Liggett; Basil Anderson; Henry Becton; Edward DeGraan; Vincent Forlenza; Christopher Jones; Marshall Larsen; Edward Ludwig; Adel Mahmoud; Gary Mecklenburg; James Orr; Willard Overlock; Bertram Scott; and Alfred Sommer.
Enzo Biochem said this week that it has re-elected Elazar Rabbani to serve as a class III director for a three-year term.
Genetic Technologies said this week that the company's Co-founder, Malcolm Simons, died last week at the age of 73. Simons held various roles at the company between 1989 and 2003, and he has been recognized as a pioneer in early studies of non-coding DNA.
The Critical Path Institute has hired Carolyn Compton as its new president and CEO. Compton is replacing Raymond Woosley, C-Path's founder, who last year announced his decision to step down from the top post at the institute. Compton previously served as the director of the Office of Biorepositories and Biospecimen Research and was the executive director of the Cancer Human Biobank project at the National Cancer Institute.
Roche said this week that it has named Dan Zabrowski as head of Roche Applied Science in the company's diagnostics division in Penzberg, Germany.
Zabrowski succeeds Paul Brown, who led Roche Applied Science since September 2011. Zabrowski will report to Daniel O'Day, COO of Roche Diagnostics.
Zabrowski most recently served as global head of Roche partnering and was a member of the Roche corporate executive committee and Chugai board. He joined Roche in 1994 through the acquisition of Syntex. During his career at Roche, Zabrowski held a number of management positions in regulatory affairs and development. He holds a PhD in organic chemistry from the University of Indiana.
PerkinElmer has elected Peter Barrett, a partner at the life sciences venture capital fund Atlas Venture, to serve on its board of directors. Before he joined Atlas Venture in 2002 Barrett was a co-founder, executive VP, and chief business officer of Celera Genomics.
Stephen O'Brien has left the National Cancer Institute's Laboratory of Genomic Diversity after 25 years to help launch a genome bioinformatics program at St. Petersburg University in Russia. O'Brien received a $5 million grant from the Russian Ministry of Education and Science last year under a program that aims to lure big-name researchers to Russia. Over the coming three years, O'Brien will spend at least four months per year in Russia working at the center, which is scheduled to open in May.
Expression Pathology has promoted Jon Burrows to be president and CEO, replacing Casey Eitner, who will remain on the board of directors. Burrows has been head of the company's R&D and executive VP since 2009, and he has held management and research posts at Ventana Medical Systems, Novartis, Chiron, and other firms.
Veracyte has tapped Mark Spring to be its chief financial officer. Spring previously was senior VP and CFO for Prometheus Laboratories, and he was senior VP and CFO at Hyperion Therapeutics.
Definiens has appointed Martin Stuart as its executive VP and GM of North America and the Asia Pacific region. Stuart is former VP and GM of the digital pathology company Aperio, and he was global VP of sales and services for Entropia.
Oxford Gene Technology founder Ed Southern has been awarded a 2011 Medical Research Council Millenium Medal, which recognizes scientists who have made major contributions to the health and wealth of society, for his work in developing microarray technologies. Southern is OGT's chairman and chief scientific officer, and he leads the company's exploratory research group.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.